TrisOxine abiotic siderophores for technetium complexation: radiolabeling and biodistribution studies.
Biodistribution
Chelates
Nano SPECT/CT imaging
Oxidation state
Radiochemical purity
Radiochemistry
Siderophores
Technetium-99m
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
received:
07
07
2023
accepted:
03
10
2023
medline:
19
10
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
epublish
Résumé
Despite the development of positron emission tomography (PET), single photon emission computed tomography (SPECT) still accounts for around 80% of all examinations performed in nuclear medicine departments. The search for new radiotracers or chelating agents for Technetium-99m is therefore still ongoing. O-TRENSOX and O-TRENOX two synthetic siderophores would be good candidates for this purpose as they are hexadentate ligands based on the very versatile and efficient 8-hydroxyquinoline chelating subunit. First, the radiolabeling of O-TRENOX and O-TRENSOX with The radiolabeling studies showed a rapid and efficient complexation of These encouraging results allow us to consider the O-TRENOX/
Sections du résumé
BACKGROUND
BACKGROUND
Despite the development of positron emission tomography (PET), single photon emission computed tomography (SPECT) still accounts for around 80% of all examinations performed in nuclear medicine departments. The search for new radiotracers or chelating agents for Technetium-99m is therefore still ongoing. O-TRENSOX and O-TRENOX two synthetic siderophores would be good candidates for this purpose as they are hexadentate ligands based on the very versatile and efficient 8-hydroxyquinoline chelating subunit. First, the radiolabeling of O-TRENOX and O-TRENSOX with
RESULTS
RESULTS
The radiolabeling studies showed a rapid and efficient complexation of
CONCLUSIONS
CONCLUSIONS
These encouraging results allow us to consider the O-TRENOX/
Identifiants
pubmed: 37856008
doi: 10.1186/s41181-023-00214-2
pii: 10.1186/s41181-023-00214-2
pmc: PMC10587049
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32Informations de copyright
© 2023. Springer Nature Switzerland AG.
Références
Nucl Med Biol. 2021 Jan;92:202-216
pubmed: 32475681
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):1990-2012
pubmed: 31273437
Food Funct. 2018 Jun 20;9(6):3114-3125
pubmed: 29876541
Int J Appl Radiat Isot. 1982 Feb;33(2):93-7
pubmed: 6460703
Mol Imaging Biol. 2003 Nov-Dec;5(6):376-89
pubmed: 14667492
Molecules. 2022 Apr 19;27(9):
pubmed: 35565970
Inorg Chem. 2022 Dec 26;61(51):20964-20976
pubmed: 36516446
Int J Mol Sci. 2022 Apr 30;23(9):
pubmed: 35563414
J Nucl Med. 1977 Nov;18(11):1099-105
pubmed: 915087
J Inorg Biochem. 2002 Apr 10;89(1-2):123-30
pubmed: 11931972
Bioconjug Chem. 2004 Jul-Aug;15(4):856-63
pubmed: 15264874
Molecules. 2022 Dec 26;28(1):
pubmed: 36615397
J Nucl Med. 1977 May;18(5):455-61
pubmed: 870637
Mol Biol Rep. 2018 Dec;45(6):2717-2723
pubmed: 30328001
J Labelled Comp Radiopharm. 2016 Oct;59(12):517-530
pubmed: 27611733
Int J Rad Appl Instrum B. 1992 May;19(4):491-6
pubmed: 1526813
Med Sci (Paris). 2015 Aug-Sep;31(8-9):756-63
pubmed: 26340835
Int J Radiat Biol. 2018 Jun;94(6):590-596
pubmed: 29659318
Br J Haematol. 1983 Jan;53(1):31-41
pubmed: 6401210
J Nucl Med. 1980 Jul;21(7):662-9
pubmed: 7391841
Biometals. 2006 Aug;19(4):349-66
pubmed: 16841245